BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36878533)

  • 1. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
    Liu LL; Skribek M; Harmenberg U; Gerling M
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
    Rajapakse P; Andanamala H
    World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapy.
    Heynemann S; Vanguru V; Adelstein S; Kao S
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):315-318. PubMed ID: 36562695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.
    Ceschi A; Noseda R; Palin K; Verhamme K
    Front Pharmacol; 2020; 11():557. PubMed ID: 32425791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
    Tay SH; Toh MMX; Thian YL; Vellayappan BA; Fairhurst AM; Chan YH; Aminkeng F; Bharwani LD; Huang Y; Mak A; Wong ASC
    Front Immunol; 2022; 13():807050. PubMed ID: 35154124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
    Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
    BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F; Hogan S; Menzies AM; Dummer R; Long GV
    Eur J Cancer; 2021 Nov; 157():214-224. PubMed ID: 34536945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
    Wei Y; He W; Sun W; Wu C; Ren D; Wang X; Zhang M; Huang M; Ji N
    Transl Cancer Res; 2022 Aug; 11(8):2960-2966. PubMed ID: 36093533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
    Xu Z; Li H; Yu X; Luo J; Zhang Z
    Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
    Mascolo A; Scavone C; Ferrajolo C; Rafaniello C; Danesi R; Del Re M; Russo A; Coscioni E; Rossi F; Alfano R; Capuano A
    Drug Saf; 2021 Sep; 44(9):957-971. PubMed ID: 34145536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
    Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
    JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
    Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
    Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
    J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.